Global /United States /Healthcare /Drug Manufacturers - General /IMMX

Immix Biopharma, Inc.

IMMX

• NASDAQ: IMMX • Delayed

8.63USD 0.4%

As of 13 June 2026, Immix Biopharma, Inc. has a market cap of $457.49M USD, ranking #15751 globally and #2700 in the United States. It ranks #1409 in the Healthcare sector, and #516 in the Drug Manufacturers - General industry.

Global Rank

15751

Country Rank

2700

Sector Rank

1409

Industry Rank

516

Key Stats

Market Cap

$457.49MUSD

Enterprise Value

$357.1MUSD

EBITDA (TTM)

-$29.71MUSD

Net Income (TTM)

-$29.44MUSD

PB Ratio

4.9

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Ilya Rachman open_in_new

Employees

Founded

2014

IPO

16 Dec 2021

Website

immixbio.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0.4%	-11%	5.5%	40%	121%	64%	343%	248%	69%

News

IMMX Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	IMMX Immix Biopharma Inc ISIN: US45258H1068 Shares Out.: Shares Outstanding: 71.19M¹ Shares Float: 54.47M² TV: TradingView: NASDAQ: IMMX SA: Stock Analysis: NASDAQ: IMMX YF: Yahoo Finance: IMMX GF: Google Finance: NASDAQ: IMMX NQ: NASDAQ: IMMX BA: Barron's: IMMX MS: Morningstar: XNAS: IMMX	8.63 USD	TV: TradingView: NASDAQ: IMMX SA: Stock Analysis: NASDAQ: IMMX YF: Yahoo Finance: IMMX GF: Google Finance: NASDAQ: IMMX NQ: NASDAQ: IMMX BA: Barron's: IMMX MS: Morningstar: XNAS: IMMX

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Immix Biopharma, Inc.

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 166K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 120K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 79K%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 60K%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 33K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 26K%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 70K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 63K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 60K%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 40K%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 24K%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 24K%	14.6	United Kingdom

chevron_leftBack